Gentian Diagnostics Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Gentian Diagnostics de 63.5% y 25.7% respectivamente, mientras que el BPA crecerá en un 103.3% al año.

Información clave

63.5%

Tasa de crecimiento de los beneficios

103.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	18.9%
Tasa de crecimiento de los ingresos	25.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14

Recent updates

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Jun 29

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Oct 28

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

May 11

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

Mar 20

Previsiones de crecimiento de beneficios e ingresos

OB:GENT - Estimaciones futuras de los analistas y datos financieros pasados (NOK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	261	32	N/A	N/A	1
12/31/2025	201	23	21	31	1
12/31/2024	151	16	8	18	1
9/30/2024	154	2	22	31	N/A
6/30/2024	153	-2	5	13	N/A
3/31/2024	149	-6	15	21	N/A
12/31/2023	142	-11	11	15	N/A
9/30/2023	129	-5	-12	-7	N/A
6/30/2023	122	-14	-6	0	N/A
3/31/2023	120	-18	-19	-6	N/A
12/31/2022	112	-24	-29	-14	N/A
9/30/2022	106	-29	-34	-19	N/A
6/30/2022	100	-26	-43	-26	N/A
3/31/2022	99	-26	-42	-29	N/A
12/31/2021	100	-25	-40	-27	N/A
9/30/2021	99	-19	-24	-9	N/A
6/30/2021	96	-19	-27	-16	N/A
3/31/2021	84	-17	-20	-12	N/A
12/31/2020	79	-17	-19	-13	N/A
9/30/2020	72	-21	-16	-13	N/A
6/30/2020	70	-19	-16	-13	N/A
3/31/2020	62	-38	-28	-25	N/A
12/31/2019	55	-40	-26	-21	N/A
9/30/2019	44	-46	-25	-20	N/A
6/30/2019	48	-41	-22	-17	N/A
3/31/2019	47	-23	-18	-12	N/A
12/31/2018	46	-20	-17	-11	N/A
9/30/2018	51	-12	-23	-18	N/A
6/30/2018	41	-16	N/A	-19	N/A
3/31/2018	40	-14	N/A	-16	N/A
12/31/2017	35	-15	N/A	-19	N/A
9/30/2017	34	-13	N/A	-19	N/A
6/30/2017	32	-12	N/A	-18	N/A
3/31/2017	30	-13	N/A	-16	N/A
12/31/2016	31	-9	N/A	-8	N/A
12/31/2015	26	-3	N/A	-5	N/A
12/31/2014	25	-3	N/A	-2	N/A
12/31/2013	23	1	N/A	2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (63.5% al año) de GENT es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (63.5% al año) de GENT crezcan más rápidamente que el mercado Norwegian (9.3% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de GENT crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (25.7% al año) de GENT crezcan más rápidamente que los del mercado Norwegian (2.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (25.7% al año) de GENT crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de GENT se prevé que sea elevada dentro de 3 años.

Gentian Diagnostics Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target increased by 24% to kr67.00

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Consensus estimates of losses per share improve by 70%

Consensus estimates of losses per share improve by 31%

Consensus EPS estimates fall by 12%

Recent updates

Consensus revenue estimates decrease by 10%, EPS upgraded

Third quarter 2024 earnings released: EPS: kr0.22 (vs kr0.053 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.059 in 2Q 2023)

Price target increased by 24% to kr67.00

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Now 20% undervalued after recent price drop

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.043 loss in 1Q 2023)

Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO

Full year 2023 earnings released: kr0.69 loss per share (vs kr1.53 loss in FY 2022)

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Full year 2023 earnings released: kr0.67 loss per share (vs kr1.53 loss in FY 2022)

Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors

Gentian Diagnostics ASA to Report Q4, 2023 Results on Feb 09, 2024

Consensus estimates of losses per share improve by 70%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released

CFO & COO recently bought kr217k worth of stock

First quarter 2023 earnings released

Consensus estimates of losses per share improve by 31%

Full year 2022 earnings: EPS exceeds analyst expectations

Gentian Diagnostics Asa Announces New Study Addresses the Use of Plasma Calprotectin in Sepsis Management

Consensus EPS estimates fall by 12%

Price target decreased by 43% to kr52.00

Gentian Diagnostics ASA Announces Executive Changes, Effective from 1 January 2023

Gentian Diagnostics ASA to Report Q4, 2022 Results on Feb 16, 2023

Gentian Diagnostics ASA, Annual General Meeting, May 04, 2023

Gentian Diagnostics ASA Receives Patent for NT-proBNP in the U.S

No independent directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Consensus forecasts updated

Director recently bought kr96k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Gentian Diagnostics ASA Announces Executive Appointments

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

First quarter 2022 earnings: Revenues miss analyst expectations

No independent directors

Gentian Diagnostics Asa Announce the Release of the Novel Ce Marked Sars-Cov-2 Total Antibody Immunoassay

Director recently bought kr203k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Gentian Diagnostics AS Completes Development of SARS Cov-2 Antibody Assay

Third quarter 2021 earnings released

Price target increased to kr104

Second quarter 2021 earnings released: kr0.23 loss per share (vs kr0.092 loss in 2Q 2020)

First quarter 2021 earnings released

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Gentian Diagnostics as Announces Publication of NT-ProBNP Patent Application

Full year 2020 earnings released: kr1.13 loss per share (vs kr2.59 loss in FY 2019)

Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

New 90-day low: kr52.50

New 90-day low: kr56.00

Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?

Gentian Diagnostics AS Announces New Study Results Confirm the Value of Calprotectin in Management of COVID-19 Patients

New 90-day low: kr60.50

Third quarter earnings released

Insider recently sold kr3.0m worth of stock

Earnings released

New 90-day high - kr64.00

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento